Ursofalk Warnings

Capsule: Ursodeoxycholic acid (Ursofalk) 250 mg capsules must be used under medical supervision. Doctor should test liver function regularly every 4 weeks for the first 3 months of treatment. After this time, it should be monitored at 3-month intervals.
When used to dissolve gallstones, the doctor should arrange for a scan of the patient's gall bladder after the first 6-10 months of treatment.
If the patient is a woman and take this medicine for dissolution of gallstones the patient should use an effective non-hormonal method of contraception, since hormonal contraceptives may encourage the formation of gallstones.
When used in the treatment of PBC, in rare cases the symptoms (e.g. itching) may worsen at the beginning of treatment. If this happens, please speak to the doctor about reducing the initial dose.
Tell the doctor immediately if the patient is suffering from diarrhoea, as the patient may need the dose to be reduced or to stop taking Ursodeoxycholic acid (Ursofalk) 250 mg capsules.
Long-term, high-dose Ursodeoxycholic acid therapy (28-30 mg/kg/day) in patients with primary sclerosing cholangitis was associated with higher rates of serious adverse events.